Background: The ALEX study (NCT02075840) showed superior investigator (INV)assessed PFS with ALC vs crizotinib (CZ) (stratified HR 0.47, 95% CI 0.34-0.65, p < 0.001): median PFS not estimable ALC vs 11.1 months [m] CZ. Follow-up analysis (cut-off Dec 1 2017) indicated a median PFS of 34.8m ALC vs 10.9m CZ (stratified HR 0.43, 95% CI 0.32-0.58) [Camidge et al. ASCO 2018]. We report efficacy data from ALEX by EML4-ALK variant group. Methods: Patients (pts) with stage IIIB/IV ALKþ NSCLC (by central IHC) and no prior systemic therapy for aNSCLC were enrolled (asymptomatic CNS metastases allowed) and randomized 1:1 to receive ALC 600mg BID (n ¼ 152) or CZ 250mg BID (n ¼ 151). ALK rearrangement was assessed in baseline samples by next generation sequencing (NGS; FoundationOne V R [tissue] and Foundation ACT [plasma]) using the primary data cut-off (Feb 9 2017). PFS (INV-assessed, RECIST v1.1), objective response rate (ORR) and duration of response (DoR) were assessed by EML4-ALK variant. Results: Baseline demographics/PFS were comparable between the biomarker evaluable populations (BEP; n ¼ 203 tissue, n ¼ 222 plasma) and the ITT population (n ¼ 303). ALK rearrangement was detected by NGS in 136/203 (67%; tissue) and 145/ 222 (65%; plasma) pts. EML4-ALK variants 1, 2 and 3a/b accounted for $90% of variants (variant 2 was least prevalent). In the primary data set analysis, no significant difference was observed in INV-assessed PFS or ORR between the EML4-ALK variant groups in both tissue and plasma BEPs for ALC-and CZ-treated pts (Table) . Median DoR was similar for EML4-ALK variants 1, 2 and 3 in the ALC arm but not in the CZ arm. Efficacy data by independent review were comparable. Conclusions: These exploratory post-hoc analyses from the ALEX study show that the greater efficacy benefit of ALC vs CZ in ALKþ aNSCLC appeared independent of the EML4-ALK variant.
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